drugset / Trial / NCT04739423
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
RandomizedCrossoverQuadruple-blindTreatment
Summary
This is a Phase II, randomized, placebo-controlled, double-blind, crossover study on the CNS and pharmacodynamic effects of clenbuterol (CST-103) co-administered with nadolol (CST-107) in 4 subject populations with Neurodegenerative Disorders.
Timeline
- Start
- 2021-06-28
- Primary completion
- 2022-07-04
- Completion
- 2022-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clenbuterol | Small molecule | — | — |
| Subject | Nadolol | Unknown | — | — |